Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018
February 28, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
February 28, 2018 is the 11th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the...
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
February 26, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results
February 22, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief...
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
CORRECTION - Achillion Pharmaceuticals, Inc.
December 20, 2017 12:12 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
December 20, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
December 18, 2017 06:30 ET
|
Achillion Pharmaceuticals, Inc.
- Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) – - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in...
Achillion Announces Pricing of Secondary Offering Of Common Stock
November 15, 2017 22:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of...
Achillion Announces Proposed Secondary Offering of Common Stock
November 14, 2017 16:03 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ:ACHN) today announced that Johnson & Johnson Innovation-JJDC, Inc. (“JJDC”), an existing...
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
November 14, 2017 16:01 ET
|
Achillion Pharmaceuticals, Inc.
- Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471 - - Improvement in complement alternative pathway biomarkers observed - ...